Histone demethylase inhibitors
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
1. A compound of Formula (XIb), or a pharmaceutically acceptable salt thereof,
wherein,
R 1 is hydrogen, methyl, or —OH;
R 6 is hydrogen; and
R 5 , R 7 and R 8 are each independently chosen from hydrogen, halogen, —OH, —CN, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxy, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted C 3 -C 7 carbocyclyloxy, optionally substituted C 4 -C 12 carbocyclylalkyl, optionally substituted C 4 -C 12 carbocyclylalkoxy, optionally substituted C 1 -C 6 alkynyl, optionally substituted C 1 -C 6 alkenyl, optionally substituted C 6 -C 10 aryl, optionally substituted C 6 -C 10 aryloxy, optionally substituted C 6 -C 10 aryl-S—, optionally substituted C 7 -C 14 aralkoxy, optionally substituted heteroaryl, and optionally substituted heteroaryloxy.
2. The compound of claim 1 , wherein R 1 is hydrogen.
3. The compound of claim 1 , wherein R 5 is hydrogen.
4. The compound of claim 1 , wherein R 7 is hydrogen.
5. The compound of claim 1 , wherein R 8 is hydrogen.
6. The compound of claim 1 , wherein R 5 and R 7 are hydrogen.
7. The compound of claim 1 , wherein R 5 and R 8 are hydrogen.
8. The compound of claim 1 , wherein R 7 and R 8 are hydrogen.
9. A pharmaceutical composition comprising a pharmaceutical acceptable carrier and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.